HSBC Holdings
ABCL icon

HSBC Holdings’s AbCellera Biologics ABCL Stock Holding History

HSBC Holdings’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$499K Buy
143,472
+26,441
+23% +$95.1K ﹤0.01% 2227
2025
Q4 		$401K Buy
117,031
+92,414
+375% +$413K ﹤0.01% 2405
2025
Q3 		$123K Buy
24,617
+4,524
+23% +$19.9K ﹤0.01% 2573
2025
Q2 		$71.3K Sell
20,093
-251
-1% -$625 ﹤0.01% 2898
2025
Q1 		$45K Sell
20,344
-1,155
-5% -$3.31K ﹤0.01% 2917
2024
Q4 		$62.5K Buy
21,499
+2
+0% +$6 ﹤0.01% 2961
2024
Q3 		$56.4K Hold
21,497
– – ﹤0.01% 2873
2024
Q2 		$63.4K Sell
21,497
-68,403
-76% -$259K ﹤0.01% 2798
2024
Q1 		$407K Sell
89,900
-424
-0.5% -$2.16K ﹤0.01% 2209
2023
Q4 		$513K Buy
90,324
+56,526
+167% +$262K ﹤0.01% 2042
2023
Q3 		$155K Buy
33,798
+19,274
+133% +$117K ﹤0.01% 2481
2023
Q2 		$93.9K Buy
+14,524
New +$99.1K ﹤0.01% 2437
2022
Q4 		– Sell
-79,799
Closed -$797K – 3040
2022
Q3 		$797K Buy
79,799
+19,492
+32% +$214K ﹤0.01% 1934
2022
Q2 		$650K Buy
+60,307
New +$511K ﹤0.01% 2172

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HSBC Holdings's ABCL Position: Q1 2026 in Review

HSBC Holdings increased its AbCellera Biologics (ABCL) stake by 23% in Q1 2026, buying an estimated $95.1K and bringing the position to 143,472 shares worth $499K. The position accounts for ﹤0.01% of the portfolio, ranked #2227.

HSBC Holdings first reported a position in ABCL in Q2 2022 and has held it in 14 quarters since. The position peaked at $797K in Q3 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • HSBC Holdings held 143,472 shares of AbCellera Biologics worth $499K as of Q1 2026.
  • HSBC Holdings bought 26,441 AbCellera Biologics shares in Q1 2026, an estimated $95.1K.
  • AbCellera Biologics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2227 holding.
  • HSBC Holdings first reported a position in AbCellera Biologics in Q2 2022 and has held it in 14 quarters since.
  • HSBC Holdings's AbCellera Biologics position peaked at $797K in Q3 2022.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.